1999
DOI: 10.1016/s0065-3519(99)80032-9
|View full text |Cite
|
Sign up to set email alerts
|

Present Uses of and Experiences with Swine Vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
9
0

Year Published

2000
2000
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 1 publication
0
9
0
Order By: Relevance
“…However, A. pleuropneumoniae has been divided into 15 serotypes (4), with the lack of cross-protection between the main serotypes (5, 6) resulting in slow progress in the development of vaccines. To date, many studies have been reported and several vaccines have been commercialized, but complete satisfaction has not been obtained in the protection of pigs against A. pleuropneumoniae infection (7,8). Therefore, the development of new vaccines is urgently required.…”
mentioning
confidence: 99%
“…However, A. pleuropneumoniae has been divided into 15 serotypes (4), with the lack of cross-protection between the main serotypes (5, 6) resulting in slow progress in the development of vaccines. To date, many studies have been reported and several vaccines have been commercialized, but complete satisfaction has not been obtained in the protection of pigs against A. pleuropneumoniae infection (7,8). Therefore, the development of new vaccines is urgently required.…”
mentioning
confidence: 99%
“…B. bronchiseptica is also a contributory agent in the porcine respiratory disease complex, a multifactorial disease state that is increasingly problematic for swine producers (2). However, vaccine efficacy is reported to be low, and atrophic rhinitis remains an important disease problem in grower/finisher pigs (1,34).…”
mentioning
confidence: 99%
“…Despite widespread use of B. bronchiseptica vaccines by swine producers throughout the world, respiratory disease associated with this agent remains a significant problem for the industry (5,54). The development of vaccines with improved efficacy is hindered by the absence of definitive data related to virulence mechanisms of B. bronchiseptica in swine.…”
Section: Discussionmentioning
confidence: 99%
“…Despite vaccination rates of up to 42%, only 10.5% of swine herds in the United States are free from atrophic rhinitis (54). A more recent study indicates that although B. bronchiseptica vaccines continue to be widely utilized by swine producers in both the United States and Europe, their effectiveness is questionable (5). B. bronchiseptica is also one of the agents involved in porcine respiratory disease complex, a multifactorial disease state that has been of increasing concern to swine producers since the early 1990s (7).…”
mentioning
confidence: 99%